Literature DB >> 23255800

Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Stéphanie Cordeil1, Xuan-Nhi Nguyen, Gregory Berger, Stéphanie Durand, Michelle Ainouze, Andrea Cimarelli.   

Abstract

Type I interferons induce a complex transcriptional program that leads to a generalized antiviral response against a large panel of viruses, including human immunodeficiency virus type 1 (HIV-1). However, despite the fact that interferons negatively regulate HIV-1 ex vivo, a chronic interferon state is linked to the progression of AIDS and to robust viral replication, rather than protection, in vivo. To explain this apparent contradiction, we hypothesized that HIV-1 may have evolved a partial resistance to interferon, and to test this hypothesis, we analyzed the effects of alpha interferon (IFN-α) on the infectivity of HIV-1, human immunodeficiency virus type 2 (HIV-2), and rhesus monkey simian immunodeficiency virus (SIVmac). The results we obtained indicate that HIV-1 is more resistant to an IFN-α-induced response than are HIV-2 and SIVmac. Our data indicate that the accumulation of viral DNA is more compromised following the infection of IFN-α-treated cells with HIV-2 and SIVmac than with HIV-1. This defect correlates with a faster destabilization of HIV-2 viral nucleoprotein complexes (VNCs), suggesting a link between VNC destabilization and impaired viral DNA (vDNA) accumulation. The differential susceptibilities to IFN-α of the primate lentiviruses tested here do not map to the capsid protein (CA), excluding de facto a role for human tripartite motif protein isoform 5 alpha (Trim5α) in this restriction; this also suggests that an additional restriction mechanism differentially affects primate lentivirus infection. The different behaviors of HIV-1 and HIV-2 with respect to IFN-α responses may account at least in part for the differences in pathogenesis observed between these two virus types.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255800      PMCID: PMC3571359          DOI: 10.1128/JVI.02553-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation.

Authors:  Jenice D'Costa; Heidi M Brown; Priya Kundra; Alberta Davis-Warren; Suresh K Arya
Journal:  J Gen Virol       Date:  2001-02       Impact factor: 3.891

2.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.

Authors:  Neeltje A Kootstra; Carsten Munk; Nina Tonnu; Nathaniel R Landau; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-23       Impact factor: 11.205

4.  Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors.

Authors:  J M Azevedo-Pereira; Q Santos-Costa; K Mansinho; J Moniz-Pereira
Journal:  Virology       Date:  2003-08-15       Impact factor: 3.616

5.  The packaging signal of simian immunodeficiency virus is upstream of the major splice donor at a distance from the RNA cap site similar to that of human immunodeficiency virus types 1 and 2.

Authors:  P M Strappe; J Greatorex; J Thomas; P Biswas; E McCann; A M L Lever
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

6.  Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

Authors:  Brett M Forshey; Uta von Schwedler; Wesley I Sundquist; Christopher Aiken
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.

Authors:  Caroline Goujon; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.

Authors:  Ana E Sousa; Jorge Carneiro; Martin Meier-Schellersheim; Zvi Grossman; Rui M M Victorino
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

9.  Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag.

Authors:  Matthew W Woods; Jenna N Kelly; Clayton J Hattlmann; Jessica G K Tong; Li S Xu; Macon D Coleman; Graeme R Quest; James R Smiley; Stephen D Barr
Journal:  Retrovirology       Date:  2011-11-17       Impact factor: 4.602

10.  Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo.

Authors:  Melissa Swiecki; Yaming Wang; William Vermi; Susan Gilfillan; Robert D Schreiber; Marco Colonna
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

View more
  9 in total

Review 1.  New insights into an X-traordinary viral protein.

Authors:  Torsten Schaller; Hélène Bauby; Stéphane Hué; Michael H Malim; Caroline Goujon
Journal:  Front Microbiol       Date:  2014-04-08       Impact factor: 5.640

2.  IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity.

Authors:  Kevin Tartour; Romain Appourchaux; Julien Gaillard; Xuan-Nhi Nguyen; Stéphanie Durand; Jocelyn Turpin; Elodie Beaumont; Emmanuelle Roch; Gregory Berger; Renaud Mahieux; Denys Brand; Philippe Roingeard; Andrea Cimarelli
Journal:  Retrovirology       Date:  2014-11-25       Impact factor: 4.602

3.  HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.

Authors:  Lise Chauveau; Isabel Puigdomenech; Diana Ayinde; Ferdinand Roesch; Françoise Porrot; Daniela Bruni; Benoit Visseaux; Diane Descamps; Olivier Schwartz
Journal:  Retrovirology       Date:  2015-01-13       Impact factor: 4.602

4.  Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.

Authors:  João I Mamede; Florence Damond; Ariel de Bernardo; Sophie Matheron; Diane Descamps; Jean-Luc Battini; Marc Sitbon; Valérie Courgnaud
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

5.  The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.

Authors:  Suzannah J Rihn; Toshana L Foster; Idoia Busnadiego; Muhamad Afiq Aziz; Joseph Hughes; Stuart J D Neil; Sam J Wilson
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor.

Authors:  Caroline Goujon; Olivier Moncorgé; Hélène Bauby; Tomas Doyle; Wendy S Barclay; Michael H Malim
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

7.  Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply.

Authors:  Loic Dragin; Laura Anh Nguyen; Hichem Lahouassa; Adèle Sourisce; Baek Kim; Bertha Cecilia Ramirez; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2013-03-11       Impact factor: 4.602

8.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.

Authors:  Caroline Goujon; Olivier Moncorgé; Hélène Bauby; Tomas Doyle; Christopher C Ward; Torsten Schaller; Stéphane Hué; Wendy S Barclay; Reiner Schulz; Michael H Malim
Journal:  Nature       Date:  2013-09-18       Impact factor: 49.962

9.  A Novel Entry/Uncoating Assay Reveals the Presence of at Least Two Species of Viral Capsids During Synchronized HIV-1 Infection.

Authors:  Claire Da Silva Santos; Kevin Tartour; Andrea Cimarelli
Journal:  PLoS Pathog       Date:  2016-09-30       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.